The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
Open accessAbstract
BACKGROUND: On the base of the microRNA (miRNA) expression signature of bladder cancer (BC), we found that miR-1 and miR-133a were significantly downregulated in BC. In this study, we focussed on the functional significance of miR-1 and miR-133a in BC cell lines and identified a molecular network of these miRNAs. METHODS AND RESULTS: We investigated the miRNA expression signature of BC clinical specimens and identified several downregulated miRNAs (miR-133a, miR-204, miR-1, miR-139-5p, and miR-370). MiR-1 and miR-133a showed potential role of tumour suppressors by functional analyses of BC cells such as cell proliferation, apoptosis, migration, and invasion assays. Molecular target searches of these miRNAs showed that transgelin 2 (TAGLN2) was directly regulated by both miR-1 and miR-133a. Silencing of TAGLN2 study demonstrated significant inhibitions of cell proliferation and increase of apoptosis in BC cell lines. The immunohistochemistry showed a positive correlation between TAGLN2 expression and tumour grade in clinical BC specimens. CONCLUSIONS: The downregulation of miR-1 and miR-133a was a frequent event in BC, and these miRNAs were recognised as tumour suppressive. TAGLN2 may be a target of both miRNAs and had a potential oncogenic function. Therefore, novel molecular networks provided by miRNAs may provide new insights into the underlying molecular mechanisms of BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Datta, J., Kutay, H., Nasser, M. W., Nuovo, G. J., Wang, B., Majumder, S., Liu, C.-G., Volinia, S., Croce, C. M., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6655 · Cited by 438
RetractedNasser, M. W., Datta, J., Nuovo, G., Kutay, H., Motiwala, T., Majumder, S., Wang, B., Suster, S., Jacob, S. T., & Ghoshal, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804788200 · Cited by 360
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation
Chen, J.-F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M., Conlon, F. L., & Wang, D.-Z. (2006) · Nature Genetics · doi:10.1038/ng1725 · Cited by 2,779
Cited by
microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers
Nohata, N., Hanazawa, T., Enokida, H., & Seki, N. (2012) · Oncotarget · doi:10.18632/oncotarget.424 · Cited by 253
Self-citationMicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma
Yoshino, H., Tatarano, S., Tamai, M., Tsuruda, M., Iizasa, S., Arima, J., Kawakami, I., Fukumoto, W., Kawahara, I., Li, G., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.056 · Cited by 24
Self-citation
Metadata
- Authors
- Yoshino, H., Chiyomaru, T., Enokida, H., Kawakami, K., Tatarano, S., Nishiyama, K., Nohata, N., Seki, N., & Nakagawa, M.
- Venue
- British Journal of Cancer
- Published
- 2011-02-08
- Volume
- 104
- Issue
- 5
- Pages
- 808-818
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1975787075
- Cited by
- 273
- References
- 37
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. https://app.cochat.ai/papers/10.1038/bjc.2011.23
- The paper
- Yoshino, H., Chiyomaru, T., Enokida, H., Kawakami, K., Tatarano, S., Nishiyama, K., Nohata, N., Seki, N., & Nakagawa, M. (2011). The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2011.23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.